PT - JOURNAL ARTICLE ED - , TI - Managing scarlet fever AID - 10.1136/dtb.2017.8.0529 DP - 2017 Sep 01 TA - Drug and Therapeutics Bulletin PG - 102--102 VI - 55 IP - 9 4099 - http://dtb.bmj.com/content/55/9/102.2.short 4100 - http://dtb.bmj.com/content/55/9/102.2.full SO - Drug Ther Bull2017 Sep 01; 55 AB - Scarlet fever, an infection caused by toxin-producing strains of Streptococcus pyogenes, was associated with high levels of morbidity and mortality when epidemics were common in the 18th and 19th centuries throughout Europe and the USA.1 Although this disease nearly disappeared during the 20th century, several countries, including the UK, have recently experienced a re-emergence of scarlet fever.1-3 However, the reason for these new outbreaks remains unclear.1,4 Despite a general move to reduce the use of antibiotics for many mild self-limiting infections (e.g. tonsillitis, sinusitis), national guidance recommends treating people with scarlet fever with antibiotics regardless of severity of illness to speed recovery, to reduce the length of time the infection is contagious and to reduce the risk of complications.5,6 Here, we discuss the management of scarlet fever in the UK.